On June 29th, MBBP client Allegro Diagnostics, Inc. announced that it has entered into an exclusive license agreement with MBBP client Boston University and the University of Utah Foundation for intellectual property related to Allegro Diagnostics’ molecular testing platform which utilizes a genomic biomarker to detect early signs of lung cancer. Mike Webb, President and CEO of Allegro Diagnostics, describes the agreement:
Allegro Diagnostics is committed to bringing early lung cancer detection to the standard of care. The licensing agreement with Boston University and the University of Utah Foundation helps us to achieve that goal by supporting our continued advancement of this breakthrough platform, including the planned commercial launch of BronchoGen™ in the first half of 2012.
For more information please read the full press release.